Seizures Newswire

Comprehensive Real-Time News Feed for Seizures.

Results 1 - 20 of 293 in Seizures

  1. Combining benzodiazepines with other substances raises risksRead the original story

    Thursday | PressReleasePoint

    Benzodiazepines, such as alprazolam, diazepam, clonazepam and lorazepam, are a class of drugs used to relieve symptoms of anxiety, panic attacks and seizures. They are usually safe when taken as prescribed and directed under a health professional's supervision.

    Comment?

  2. Bial Release: Targeting Pharmacoresistant Epilepsy And...Read the original story

    Tuesday Dec 16 | BioSpace

    ... in the European Union (Zebinix ), United States and Canada (Aptiom ), for the adjunctive treatment of partial-onset seizures in adults (2,3). Chronically epileptic tissue was obtained from epileptic patients that underwent brain surgery in an ...

    Comment?

  3. Nicotine patch stops child's seizuresRead the original story w/Photo

    Wednesday Dec 17 | News 4 Jax

    ... nicotine patch was just enough to do the trick. "Every single night she was having an average of 20 seizures," said Ki Hyeong Lee, M.D., Medical Director of the Comprehensive Epileptic Center at Florida Hospital for Children, Orlando. "We tried ...

    Comment?

  4. Nicotine patch ends seizures for 5-year-old girlRead the original story w/Photo

    Friday Dec 12 | WNDU-TV South Bend

    ... available nicotine patch, was just enough to do the trick. "Every single night, she was having an average of 20 seizures," says Ki Hyeong Lee, medical director for the epilepsy program at Florida Hospital for Children. Dr. Lee says Karen's genetic ...

    Comment?

  5. FDA gives approval for marijuana oil studyRead the original story w/Photo

    Thursday Dec 11 | WSFA-TV Montgomery

    The Food and Drug Administration is giving the University of Alabama at Birmingham the green light to study the use of a marijuana derivative to treat seizures. Parents of children with seizure disorders persuaded the Alabama Legislature last year to pass a bill authorizing UAB's Department of Neurology to do a study of the marijuana derivative cannabidiol as a seizure treatment.

    Comment?

  6. FDA Gives Approval for Marijuana Oil StudyRead the original story w/Photo

    Thursday Dec 11 | WTVY Dothan

    The Food and Drug Administration is giving the University of Alabama at Birmingham the green light to study the use of a marijuana derivative to treat seizures. Parents of children with seizure disorders persuaded the Alabama Legislature last year to pass a bill authorizing UAB's Department of Neurology to do a study of the marijuana derivative cannabidiol as a seizure treatment.

    Comment?

  7. Primary data from Phase 3 study evaluating brivaracetam as adjunctive ...Read the original story w/Photo

    Thursday Dec 11 | Medical News Today

    UCB has announced the primary efficacy and safety data from the latest Phase 3 study evaluating brivaracetam as adjunctive treatment in adult epilepsy patients with partial-onset seizures.1 This study with brivaracetam represents the largest Phase 3 study conducted in epilepsy patients with partial-onset seizures. Brivaracetam is an investigational antiepileptic drug and is not approved by any regulatory authority worldwide.

    Comment?

  8. Hot-button issues await start of legislative sessionRead the original story w/Photo

    Tuesday Dec 9 | Effingham Herald

    ... State lawmakers will begin the next session under the Gold Dome on Jan. 12. The use of medical marijuana to treat seizures in children didn't pass last year, but Rep. Allen Peake (R-Macon), who has led a study committee into medical marijuana and ...

    Comment?

  9. Eisai Presents Results from Phase III Trial of Antiepileptic Drug...Read the original story

    Tuesday Dec 9 | JCN Network

    Tokyo, Dec 9, 2014 - - Eisai Co., Ltd. announced today that it has presented the results from a Phase III clinical study of its in-house developed antiepileptic drug Fycompa in patients with primary generalized tonic-clonic seizures, one of the most severe forms of generalized seizures. The data was presented at the 68th American Epilepsy Society Annual Meeting held from December 5 to 9 in Seattle, Washington in the United States .

    Comment?

  10. Epilepsy and a purified form of cannabis: New reports of epidiolex(r) efficacy and safetyRead the original story w/Photo

    Monday Dec 8 | Science Daily

    Three new studies explore the efficacy and safety in the development of a purified and formulated form of cannabis called Epidiolex. Anecdotal experience and emerging data suggest that CBD might be a promising treatment for the control of seizures and systematic investigation is underway.

    Comment?

  11. Patient use of cannabis in epilepsyRead the original story w/Photo

    Monday Dec 8 | Science Daily

    ... than 50% than families who were already in Colorado. Adverse effects occurred in 47% of patients, with increased seizures or new seizures in 21%, somnolence/fatigue in 14%, and rare adverse events of developmental regression in 10% with one patient ...

    Comment?

  12. Efficacy and safety of new anti-epileptic drug revealed by phase III studyRead the original story w/Photo

    Sunday Dec 7 | Science Daily

    New findings from a phase 3 clinical trial suggest an additional therapeutic option may be coming down the pike. Researchers performed a randomized, double-blind, placebo-controlled study in the United States and Europe on the efficacy and safety of the drug brivaracetam, an analog of the commonly used AED levetiracetam, in adults with poorly controlled partial onset seizures.

    Comment?

  13. Seizures Therapeutic Pipeline Market Review H2 2014 Report at RnRMarketReserach.comRead the original story w/Photo

    Monday Dec 8 | PRWeb

    RnRMarketResearch.com adds Seizures Pipeline Review H2 2014 to its store. The report contains 80 pages and provides an overview of the Seizures therapeutic pipeline.

    Comment?

  14. Positive Long-Term Results Reported for Qudexy XR (Extended-Release Topiramate) in Seizure PatientsRead the original story

    Monday Dec 8 | P&T Community

    A year-long, open-label extension study has demonstrated that Qudexy XR is a generally well-tolerated adjunctive treatment option for a high proportion of patients with refractory partial-onset seizures . The PREVAIL OLE trial enrolled 97% of the participants who had completed the original randomized, double-blind, placebo-controlled, phase III PREVAIL study of Qudexy XR, a once-daily, broad-spectrum antiepileptic drug.

    Comment?

  15. Patient Use of Cannabis in Epilepsy Featured in Three New StudiesRead the original story

    Monday Dec 8 | Newswise

    ... than 50% than families who were already in Colorado. Adverse effects occurred in 47% of patients, with increased seizures or new seizures in 21%, somnolence/fatigue in 14%, and rare adverse events of developmental regression in 10% with one patient ...

    Comment?

  16. New Reports of Epidiolex(R) Efficacy and Safety Presented at the...Read the original story

    Monday Dec 8 | Newswise

    SEATTLE , December 8, 2014 - Anecdotal experience and emerging data suggest that CBD might be a promising treatment for the control of seizures and systematic investigation is underway. Three studies exploring the efficacy and safety in the development of a purified and formulated form of cannabis called Epidiolex will be presented at the 68th Annual Meeting of the American Epilepsy Society.

    Comment?

  17. Upsher-Smith Presents New Data From Year-Long, Open-Label Extension...Read the original story

    Monday Dec 8 | Applied Clinical Trials

    Upsher-Smith Presents New Data From Year-Long, Open-Label Extension Study Of Qudexy XR Extended-Release Capsules At 68th Annual American Epilepsy Society Meeting Multiple Presentations Highlight Long-Term Safety, Tolerability, and Efficacy Measures, as Adjunctive Therapy for Patients with Refractory Partial-Onset Seizures Upsher-Smith Presents New Data From Year-Long, Open-Label Extension Study Of Qudexy XR Extended-Release Capsules At 68th Annual American Epilepsy Society Meeting Multiple Presentations Highlight Long-Term Safety, Tolerability, and Efficacy Measures, as Adjunctive Therapy for Patients with Refractory Partial-Onset Seizures /PRNewswire/ -- Upsher-Smith Laboratories, Inc. presented findings from a year-long, open-label extension study of Qudexy XR extended-release capsules that demonstrated Qudexy XR as a generally well-tolerated adjunctive treatment option for a high ... (more)

    Comment?

  18. UCB Announces First Presentation Of Primary Data From Latest Phase...Read the original story

    Sunday Dec 7 | BioSpace

    Brivaracetam is an investigational antiepileptic drug and is not approved by any regulatory authority worldwide. This study showed statistical significance for the two primary endpoints one unprovoked seizure and a probability of further seizures similar to the general recurrence risk after two unprovoked seizures, occurring over the next 10 years; diagnosis of an epilepsy syndrome.

    Comment?

  19. Upsher-Smith Laboratories Release: Systematic Review Presented At...Read the original story

    Sunday Dec 7 | BioSpace

    Findings from the late-breaking abstract were presented at the 68th Annual Meeting of the American Epilepsy Society in Seizure clusters are seizures that happen one after the other over a short period of time. There is a recovery period between each seizure and a pattern that is different from the usual seizure pattern.

    Comment?

  20. "We've tried it all"Read the original story w/Photo

    Sunday Dec 7 | Denver Post

    ... down the list of anti-epilepsy medications, collecting the medical history of Ana's 12-year-old son, Preston, whose seizures cause such unrelenting brain damage that he functions at the level of a 2-year-old. The doctor ticks through 13 medicines, ...

    Comment?